Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis

  • ID: 4450629
  • Report
  • Region: Global
  • 110 Pages
  • RNCOS E-Services Private Limited
1 of 4
Approximately 15.2 Million Incidences of Cancer were Registered in 2015. This Number is Forecasted to Reach an Approximate Value of 19.3 Million and 21.6 Million by 2025 and 2030, Respectively

FEATURED COMPANIES

  • Celgene Corporation
  • Cell Medica
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Gradalis, Inc.
  • Immunocore Ltd.
  • MORE

Cancer is a class of disease which is classified by an uncontrolled cell growth. There are various types of cancer which are affecting millions of individuals all across the world. Approximately 15.2 Million incidences of cancer were registered in 2015. This number is forecasted to reach an approximate value of 19.3 Million and 21.6 Million by 2025 and 2030, respectively.

Some of the conventional treatment options for the treatment of cancer are chemotherapy and radiation therapy. Even though these treatment options help in slowing down the progression of the disease, there is no option for the complete eradication of the disease. Moreover, these conventional therapies have numerous side-effects associated with them, such as hair loss, nausea and abnormal blood cell counts. These limitations and adverse effects of conventional therapies have therefore created a significant need for the treatment of cancer with therapies having lesser side effects and better efficacy. One such novel therapy is T-cell Immunotherapy which has shown great promise in the treatment of cancer even in the advanced stages.

According to report on “Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis”, T-cell Immunotherapy is a rapidly expanding field of oncology. This therapy is intended to overcome the challenge of getting the right type of T-cell to the target tumor. It makes use of patients own immune cells to fight cancer. These immune cells are obtained from the patient and genetically engineered before their use for the treatment. Numerous researches are being performed across the globe to explore the potential of T-cell Immunotherapy for the treatment of different types of cancer. During these researches, T-cell Immunotherapies have demonstrated clinical successes on some accounts along with some critical issues on others. Overall, this therapy has emerged as one of the innovative and potent arm of the immunotherapeutic market.

The report provides an in-depth study on the current state of the T-Cell Immunotherapy industry. Recently, the USFDA approved two T-cell Immunotherapies for the treatment of cancer. The approved therapies belong to the class of CAR T-cell Immunotherapies. CAR T-cell therapies are the most researched type of therapy as they have shown exceptional results during clinical trials. The market for such T-cell Immunotherapies is forecasted to grow at an exponential rate owing to the high venture capitalist investments and increasing research related activities in this field.

Furthermore, the global and regional prevalence of major types of cancer for which T-cell Immunotherapy is used is highlighted in the report. These cancers include leukemia, lymphoma, melanoma, ovarian cancer, and bladder cancer amongst others. This will help the companies to gain knowledge regarding the target population for various immunotherapies globally, and at regional level. Moreover, an extensive analysis of the pipeline of T-cell Immunotherapies has been provided in the report. This analysis has been performed on the basis of phases, therapeutic indications, geographies, vectors used, technology types, and key players. This segment also covers the list of the key ongoing clinical trials along with their clinical phases by industry and research collaborations.

The last section of the report discusses about the key players, such as Novartis, Gilead Sciences and Juno Therapeutics among others, in the global T-cell Immunotherapy industry. A brief business overview and financial information about each of these players has been provided in the report. The product portfolio, product pipeline, recent developments and strength-weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of major players. In the end, the areas of opportunities for the growth of this industry have also been highlighted in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global T-cell Immunotherapy market.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Celgene Corporation
  • Cell Medica
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Gradalis, Inc.
  • Immunocore Ltd.
  • MORE

1. Analyst View

2. Research Methodology

3. Introduction

4. Global T-Cell Immunotherapy Market for Cancer

5. Global CAR T-Cell Immunotherapy Market for Cancer

6. Commercialized CAR T-Cell Immunotherapies for Cancer
6.1 Kymriah
6.2 Yescarta

7. Major Therapeutic Areas for T-Cell Immunotherapies
7.1 Hematological Malignancies
7.1.1 Leukemia
7.1.2 Lymphoma
7.1.3 Multiple Myeloma
7.2 Solid Tumors
7.2.1 Melanoma
7.2.2 Bladder Cancer
7.2.3 Kidney Cancer
7.2.4 Ovarian Cancer
7.2.5 Breast Cancer
7.2.6 Lung Cancer

8. T-Cell Immunotherapy Pipeline Analysis
8.1 By Industry
8.1.1 By Vector
8.1.2 By Clinical Trial Phase
8.1.3 By Indication
8.1.4 By Technology
8.1.5 By Key Players
8.1.6 By Geography
8.2 By Research Collaborations

9. Market Opportunities

10. Key Player Analysis
10.1 Adaptimmune Therapeutics plc
10.2 Juno Therapeutics, Inc.
10.3 Gilead Sciences, Inc.
10.4 Novartis International AG
10.5 Tessa Therapeutics Pte Ltd.
10.6 Gradalis, Inc.
10.7 Immunovative Therapies, Ltd.
10.8 Iovance Biotherapeutics, Inc. (Formerly Lion Biotechnologies, Inc.)
10.9 Atara Biotherapeutics, Inc.
10.10 Celgene Corporation
10.11 Cellular Biomedicine Group
10.12 GlaxoSmithKline plc.
10.13 Immunocore Ltd.
10.14 Inovio Pharmaceuticals, Inc.
10.15 Cell Medica

List of Tables:
Table 4-1: Global - Major Venture Capitalist Investment in T-Cell Immunotherapy (Million US$), 2014-2017
Table 4-2: Global - Major IPO Raised in T-Cell Immunotherapy (Million US$), 2014-2017
Table 4-3: Global - Acquisitions and Collaborations in T-Cell Immunotherapy (Million US$), 2014-2017
Table 7-1: Global - Cancer Prevalence (Million), 2015 & 2025
Table 7-2: Global - Leukemia Prevalence (‘000), 2015 & 2025
Table 7-3: North America - Leukemia Prevalence (‘000), 2015 & 2025
Table 7-4: Europe - Leukemia Prevalence (‘000), 2015 & 2025
Table 7-5: Asia-Pacific - Leukemia Prevalence (‘000), 2015 & 2025
Table 7-6: Rest of the World - Leukemia Prevalence (‘000), 2015 & 2025
Table 7-7: Global - Lymphoma Prevalence (‘000), 2015 & 2025
Table 7-8: North America - Lymphoma Prevalence (‘000), 2015 & 2025
Table 7-9: Europe - Lymphoma Prevalence (‘000), 2015 & 2025
Table 7-10: Asia-Pacific - Lymphoma Prevalence (‘000), 2015 & 2025
Table 7-11: Rest of the World - Lymphoma Prevalence (‘000), 2015 & 2025
Table 7-12: Global - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 7-13: North America - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 7-14: Europe - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 7-15: Asia-Pacific - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 7-16: Rest of the World - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 7-17: Global - Melanoma Prevalence (‘000), 2015 & 2025
Table 7-18: North America - Melanoma Prevalence (‘000), 2015 & 2025
Table 7-19: Europe - Melanoma Prevalence (‘000), 2015 & 2025
Table 7-20: Asia-Pacific - Melanoma Prevalence (‘000), 2015 & 2025
Table 7-21: Rest of the World - Melanoma Prevalence (‘000), 2015 & 2025
Table 7-22: Global - Bladder Cancer Prevalence (‘000), 2015 & 2025
Table 7-23: North America - Bladder Cancer Prevalence (‘000), 2015 & 2025
Table 7-24: Europe - Bladder Cancer Prevalence (‘000), 2015 & 2025
Table 7-25: Asia-Pacific - Bladder Cancer Prevalence (‘000), 2015 & 2025
Table 7-26: Rest of the World - Bladder Cancer Prevalence (‘000), 2015 & 2025
Table 7-27: Global - Kidney Cancer Prevalence (‘000), 2015 & 2025
Table 7-28: North America - Kidney Cancer Prevalence (‘000), 2015 & 2025
Table 7-29: Europe - Kidney Cancer Prevalence (‘000), 2015 & 2025
Table 7-30: Asia-Pacific - Kidney Cancer Prevalence (‘000), 2015 & 2025
Table 7-31: Rest of the World - Kidney Cancer Prevalence (‘000), 2015 & 2025
Table 7-32: Global - Ovarian Cancer Prevalence (‘000), 2015 & 2025
Table 7-33: North America - Ovarian Cancer Prevalence (‘000), 2015 & 2025
Table 7-34: Europe - Ovarian Cancer Prevalence (‘000), 2015 & 2025
Table 7-35: Asia-Pacific - Ovarian Cancer Prevalence (‘000), 2015 & 2025
Table 7-36: Rest of the World - Ovarian Cancer Prevalence (‘000), 2015 & 2025
Table 7-37: Global - Breast Cancer Prevalence (‘000), 2015 & 2025
Table 7-38: North America - Breast Cancer Prevalence (‘000), 2015 & 2025
Table 7-39: Europe - Breast Cancer Prevalence (‘000), 2015 & 2025
Table 7-40: Asia-Pacific - Breast Cancer Prevalence (‘000), 2015 & 2025
Table 7-41: Rest of the World - Breast Cancer Prevalence (‘000), 2015 & 2025
Table 7-42: Global - Lung Cancer Prevalence (‘000), 2015 & 2025
Table 7-43: North America - Lung Cancer Prevalence (‘000), 2015 & 2025
Table 7-44: Europe - Lung Cancer Prevalence (‘000), 2015 & 2025
Table 7-45: Asia-Pacific - Lung Cancer Prevalence (‘000), 2015 & 2025
Table 7-46: Rest of the World - Lung Cancer Prevalence (‘000), 2015 & 2025
Table 8-1: Global T-Cell Immunotherapy Pipeline by Industry
Table 8-2: Global T-Cell Immunotherapy Pipeline by Research Collaborations
Table 10-1: Adaptimmune Therapeutics plc - Revenue (Million US$), 2015 & 2016
Table 10-2: Adaptimmune Therapeutics plc - T-Cell Immunotherapy Pipeline
Table 10-3: Juno Therapeutics, Inc. - Revenue (Million US$), 2015 & 2016
Table 10-4: Juno Therapeutics, Inc. - T-Cell Immunotherapy Pipeline
Table 10-5: Gilead Sciences, Inc. - Total Revenue (Million US$), 2014, 2015 & 2016
Table 10-6: Gilead Sciences, Inc. - T-Cell Immunotherapy Product Portfolio
Table 10-7: Gilead Sciences, Inc. - T-Cell Immunotherapy Pipeline
Table 10-8: Novartis - Net Sales (Million US$), 2014, 2015 & 2016
Table 10-9: Novartis - T-Cell Immunotherapy Product Portfolio
Table 10-10: Novartis - T-Cell Immunotherapy Pipeline
Table 10-11: Tessa Therapeutics Pte Ltd. - T-Cell Immunotherapy Pipeline
Table 10-12: Gradalis, Inc. - T-Cell Immunotherapy Pipeline
Table 10-13: Immunovative Therapies, Ltd. - T-Cell Immunotherapy Pipeline
Table 10-14: Iovance Biotherapeutics, Inc. - T-Cell Immunotherapy Pipeline
Table 10-15: Atara Biotherapeutics, Inc. - T-Cell Immunotherapy Pipeline
Table 10-16: Celgene Corporation - Total Revenue (Million US$), 2014, 2015 & 2016
Table 10-17: Celgene Corporation - T-Cell Immunotherapy Pipeline
Table 10-18: Cellular Biomedicine Group - Net Sales & Revenue (Million US$), 2014, 2015 & 2016
Table 10-19: Cellular Biomedicine Group - T-Cell Immunotherapy Pipeline
Table 10-20: GlaxoSmithKline plc. - Group Turnover (Million US$), 2014, 2015 & 2016
Table 10-21: GlaxoSmithKline plc. - T-Cell Immunotherapy Pipeline
Table 10-22: Immunocore Ltd. - T-Cell Immunotherapy Pipeline
Table 10-23: Inovio Pharmaceuticals, Inc. - Total Revenue (Million US$), 2014, 2015 & 2016
Table 10-24: Inovio Pharmaceuticals, Inc. - T-Cell Immunotherapy Pipeline
Table 10-25: Cell Medica - T-Cell Immunotherapy Pipeline

List of Figures:
Figure 4-1: Global - T-Cell Immunotherapy Market for Cancer (Million US$), 2018 & 2022
Figure 5-1: Global - CAR T-Cell Immunotherapy Market for Cancer (Million US$), 2018 & 2022
Figure 6-1: Kymriah - Estimated Sales Forecast (Million US$), 2018 & 2022
Figure 6-2: Yescarta - Estimated Sales Forecast (Million US$), 2018 & 2022
Figure 7-1: Global - Breakup of Cancer Prevalence by Region (%), 2015
Figure 7-2: Global - Breakup of Cancer Prevalence by Region (%), 2025
Figure 8-1: Global - T-Cell Immunotherapy Pipeline Analysis by Vectors (%), 2017
Figure 8-2: Global - T-Cell Immunotherapy Pipeline Analysis by Phase (%), 2017
Figure 8-3: Global - T-Cell Immunotherapy Pipeline Analysis by Therapeutic Indication (%), 2017
Figure 8-4: Global - T-Cell Immunotherapy Pipeline Analysis by Technology (%), 2017
Figure 8-5: Global - T-Cell Immunotherapy Pipeline Analysis by Key Players (%), 2017
Figure 8-6: Global - T-Cell Immunotherapy Pipeline Analysis by Geography (%), 2017
Figure 9-1: US - CAR T-Cell Immunotherapy Potential Market for Cancer (Billion US$), 2018 & 2022
Figure 9-2: Europe - CAR T-Cell Immunotherapy Potential Market for Cancer (Billion US$), 2018 & 2022

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Adaptimmune Therapeutics plc
  • Atara Biotherapeutics, Inc.
  • Celgene Corporation
  • Cell Medica
  • Cellular Biomedicine Group
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Gradalis, Inc.
  • Immunocore Ltd.
  • Immunovative Therapies, Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Iovance Biotherapeutics, Inc. (Formerly Lion Biotechnologies, Inc.)
  • Juno Therapeutics, Inc.
  • Novartis International AG
  • Tessa Therapeutics Pte Ltd.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll